Key result
CV-4151 significantly reduced the incidence of ventricular fibrillation after reperfusion compared to control (0% vs 33.3%, p<0.05) and reduced myocardial infarct size in dogs.
Why the study?
Does CV-4151 reduce myocardial damage and arrhythmias in a canine model of ischemia-reperfusion?
Population
Anesthetized, open-chested dogs subjected to 60 minutes of left anterior descending coronary artery…
Comparison
CV-4151 infused i.v. at a dose of 1 mg/kg over a… vs Control group
Design
Preclinical
Follow-up
60 minutes after reperfusion
Authors
Loading...
Hypothesis-generating for thromboxane inhibition in reperfusion injury; human trials needed before clinical consideration.
Does CV-4151 reduce myocardial damage and arrhythmias in a canine model of ischemia-reperfusion?
Absolute Event Rate: 0% vs 33.3%
p-value: p=<0.05
In a canine model of ischemia-reperfusion, the thromboxane synthetase inhibitor CV-4151 significantly reduced reperfusion-induced ventricular fibrillation and myocardial infarct size.
Imamoto et al. (1987) studied myocardial damage due to coronary occlusion and reperfusion (n=45). CV-4151 vs. control was evaluated on incidence of ventricular fibrillation after reperfusion (p=<0.05). CV-4151 significantly reduced the incidence of ventricular fibrillation after reperfusion compared to control (0% vs 33.3%, p<0.05) and reduced myocardial infarct size in dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: